Evidence map›Paper›PMID 32009304›Full record

ArticleArthritis & rheumatology (Hoboken, N.J.)2020

Muscle Weakness in Myositis: MicroRNA-Mediated Dystrophin Reduction in a Myositis Mouse Model and Human Muscle Biopsies.

Travis B Kinder, Christopher R Heier, Christopher B Tully, Jack H Van der Muelen, Eric P Hoffman, Kanneboyina Nagaraju, Alyson A Fiorillo

Open access · hybridAbstract read
In one paragraph

Article in Arthritis & rheumatology (Hoboken, N.J.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 37 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Sequence Alignment betweenJournal of personalized medicine · 2024
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Travis B KinderGeorge Washington University and Children's National Hospital, Washington, DC.ORCID 0000-0003-4161-8213
Christopher R HeierGeorge Washington University and Children's National Hospital, Washington, DC.ORCID 0000-0001-7914-2068
Christopher B TullyChildren's National Hospital, Washington, DC.ORCID 0000-0001-7151-0102
Jack H Van der MuelenChildren's National Hospital, Washington, DC.ORCID 0000-0002-4533-806X
Eric P HoffmanBinghamton University, Binghampton, New York, and ReveraGen BioPharma, Rockville, Maryland.ORCID 0000-0001-6470-5139
Kanneboyina NagarajuBinghamton University, Binghampton, New York, and ReveraGen BioPharma, Rockville, Maryland.ORCID 0000-0002-1601-8489
Alyson A FiorilloGeorge Washington University and Children's National Hospital, Washington, DC.ORCID 0000-0003-3458-8036
George Washington University Hospital · USBinghamton University · USChildren's National · US

Funding

Research_ProjectU54HD090257 · NICHD · CHILDREN'S RESEARCH INSTITUTE · PI GUAY-WOODFORD, LISA MARIE · 2016 to 2020
$5.9M
Genetics and Genomics of Muscle Postdoctoral Training ProgramT32AR056993 · NIAMS · CHILDREN'S RESEARCH INSTITUTE · PI JAISWAL, JYOTI K, PARTRIDGE, TERENCE A · 2010 to 2019
$2.2M
Dissociation of efficacy from side effects of anti-inflammatory therapies in Duchenne muscular dystrophyP50HD090254 · NICHD · CHILDREN'S RESEARCH INSTITUTE · PI CONKLIN, LAURIE S · 2019 to 2020
$1.6M
Mechanisms of anti-inflammation and membrane stabilization in muscular dystrophyR00HL130035 · NHLBI · CHILDREN'S RESEARCH INSTITUTE · PI HEIER, CHRISTOPHER RYAN · 2017 to 2019
$730k
Virus induced genetic changes in the pathogenesis of autoimmune myositisR21AI128248 · NIAID · STATE UNIVERSITY OF NY,BINGHAMTON · PI NAGARAJU, KANNEBOYINA · 2017 to 2018
$437k
Mechanisms of anti-inflammation and membrane stabilization in muscular dystrophyK99HL130035 · NHLBI · CHILDREN'S RESEARCH INSTITUTE · PI HEIER, CHRISTOPHER RYAN · 2015 to 2016
$191k
Innate immune and metabolic pathway interactions in myositisF31AR065362 · NIAMS · CHILDREN'S RESEARCH INSTITUTE · PI KINDER, TRAVIS · 2013 to 2015
$128k
National Institute of Child Health and Human Development U54HD090257NHLBI NIH HHS K99 HL130035NHLBI NIH HHS R00 HL130035NIAID NIH HHS R21 AI128248NIAMS NIH HHS F31 AR065362NIAMS NIH HHS L40 AR068727NIAMS NIH HHS L40AR070539NIAMS NIH HHS T32AR056993NICHD NIH HHS P50 HD090254NICHD NIH HHS U54 HD090257U.S. Department of Defense W81XWH-17-1-047
6 · The paper itself

Abstract

objectiveMuscle inflammation is a feature in myositis and Duchenne muscular dystrophy (DMD). Autoimmune mechanisms are thought to contribute to muscle weakness in patients with myositis. However, a lack of correlation between the extent of inflammatory cell infiltration and muscle weakness indicates that nonimmune pathologic mechanisms may play a role. The present study focused on 2 microRNA (miRNA) sets previously identified as being elevated in the muscle of patients with DMD-an "inflammatory" miRNA set that is dampened with glucocorticoids, and a "dystrophin-targeting" miRNA set that inhibits dystrophin translation-to test the hypothesis that these miRNAs are similarly dysregulated in the muscle of patients with myositis, and could contribute to muscle weakness and disease severity.

methodsA major histocompatibility complex class I-transgenic mouse model of myositis was utilized to study gene and miRNA expression and histologic features in the muscle tissue, with the findings validated in human muscle biopsy tissue from 6 patients with myositis. Mice were classified as having mild or severe myositis based on transgene expression, body weight, histologic disease severity, and muscle strength/weakness.

resultsIn mice with severe myositis, muscle tissue showed mononuclear cell infiltration along with elevated expression of type I interferon and NF-κB-regulated genes, including Tlr7 (3.8-fold increase, P < 0.05). Furthermore, mice with severe myositis showed elevated expression of inflammatory miRNAs (miR-146a, miR-142-3p, miR-142-5p, miR-455-3p, and miR-455-5p; ~3-40-fold increase, P < 0.05) and dystrophin-targeting miRNAs (miR-146a, miR-146b, miR-31, and miR-223; ~3-38-fold increase, P < 0.05). Bioinformatics analyses of chromatin immunoprecipitation sequencing (ChIP-seq) data identified at least one NF-κB consensus element within the promoter/enhancer regions of these miRNAs. Western blotting and immunofluorescence analyses of the muscle tissue from mice with severe myositis demonstrated reduced levels of dystrophin. In addition, elevated levels of NF-κB-regulated genes, TLR7, and miRNAs along with reduced dystrophin levels were observed in muscle biopsy tissue from patients with histologically severe myositis.

conclusionThese data demonstrate that an acquired dystrophin deficiency may occur through NF-κB-regulated miRNAs in myositis, thereby suggesting a unifying theme in which muscle injury, inflammation, and weakness are perpetuated both in myositis and in DMD.

Indexed as

AnimalsChromatin Immunoprecipitation SequencingDystrophinHistocompatibility Antigens Class IHumansInterferon Type IMiceMice, TransgenicMicroRNAsMuscle, SkeletalMuscle WeaknessMyositisNF-kappa BSeverity of Illness IndexToll-Like Receptor 7DystrophinHistocompatibility Antigens Class IInterferon Type IMicroRNAsNF-kappa BToll-Like Receptor 7

Identifiers

PMID32009304
PMCPMC7384101
OpenAlexW3004479726

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.